BADBIR is now open to registrations of patients commencing on the following drugs:

• Stelara (ustekinumab)
• Humira (adalimumab)
• Amgevita (adalimumab)
• Hulio (adalimumab)
• Hyrimoz (adalimumab)
• Idacio (adalimumab)
• Yuflyma (adalimumab)

If a patient is already registered on BADBIR in the conventional or small molecule cohort and has started one of these treatments, we can now resume follow-up on these patients by switching them to the biologic cohort if they started treatment after 01/01/2019. We will leave data queries on any eligible patients over the next few months confirming this before carrying out the cohort switches.

In the meantime, you can leave feedback on your patients if they fall under this scenario, and we can switch them sooner.

Please see the eligibility page for full details of the treatments we currently recruit for.

Related